Unique ID issued by UMIN | UMIN000024954 |
---|---|
Receipt number | R000028683 |
Scientific Title | Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer (additional resaerch B) |
Date of disclosure of the study information | 2016/11/24 |
Last modified on | 2019/03/08 10:12:56 |
Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer (additional resaerch B)
JACCRO CC-05/CC-06 AR B
Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer (additional resaerch B)
JACCRO CC-05/CC-06 AR B
Japan |
metastatic colorectal cancer
Gastroenterology | Gastrointestinal surgery |
Malignancy
YES
The purpose of this study is to re-analysis of relations between individual biomarker and clinical data using JACCRO CC-05AR (UMIN000004197) and CC-06 studies(UMIN00007022).
Others
We investigate biomarker as below;Gene expression of EGFR, Gene amplification, EGFR intron 1 CA repeat number, Ligand expression to EGFR, expressions of epiregulin, amphiregulin, BRAF, P13K, PTEN, BRAF 600E, P13KCA exon9/exon20 and ERCC1. Around 2,500 Gene expression analyse using HTG EdgeSeq Oncology Biomarker Panel (HTG Molecular Diagnositics, Inc.)
Correlation between the biomarkers and the response to cetuximab containing combination therapies.
Others,meta-analysis etc
20 | years-old | <= |
Not applicable |
Male and Female
(1) Patients who were treated in JACCRO CC-05 study (UMIN000004197) and in JACCRO CC-06 study (UMIN000007022) .
(2) Patients who have the paraffin-embedded section of tumor tissue.
(3) Approved to supply the sections for this research by IRB.
(4) Obtained the informed consent from the patient, if in the case of death or disappearance, approval of IRB or the representative of hospital must be taken.
(1) Patients who are regarded as inadequate for study enrollment by investigators (2) Patients who refuse to supply the section
77
1st name | |
Middle name | |
Last name | Wataru Ichikawa |
Showa University Fujigaoka Hospital
Division of Medical Oncology and Palliative Medicine
1-30 Fujigaoka, Aoba-ku, Yokohama-shi, Kanagawa 224-8503, Japan
045-971-1151
wataru@med.showa-u.ac.jp
1st name | |
Middle name | |
Last name | Masashi Fujii |
Japan Clinical Cancer Research Organization
Office
1-14-5 Ginza, Chuo-ku, Tokyo 104-0061, Japan
03-5579-9882
cc05cc06ar@jaccro.or.jp
Japan Clinical Cancer Research Organization
Japan Clinical Cancer Research Organization
Non profit foundation
NO
2016 | Year | 11 | Month | 24 | Day |
Published
Completed
2016 | Year | 09 | Month | 23 | Day |
2016 | Year | 09 | Month | 23 | Day |
2018 | Year | 08 | Month | 31 | Day |
The purpose of this study is to re-analysis of relations between individual biomarker and clinical data using JACCRO CC-05AR (UMIN000004197) and CC-06 studies(UMIN00007022).
We investigate biomarker as below;Gene expression of EGFR, Gene amplification, EGFR intron 1 CA repeat number, Ligand expression to EGFR, expressions of epiregulin, amphiregulin, BRAF, P13K, PTEN, BRAF 600E, P13KCA exon9/exon20 and ERCC1. Around 2,500 Gene expression analyse using HTG EdgeSeq Oncology Biomarker Panel (HTG Molecular Diagnositics, Inc.)
2016 | Year | 11 | Month | 22 | Day |
2019 | Year | 03 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028683
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |